Challenges and successes in developing new therapies for hepatitis C

Nature

Volumn 436, Issue 7053, 2005, Pages 953-960

  De Francesco, Raffaele ^a   Migliaccio, Giovanni ^a  

^a IRBM   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG PRODUCTS; HEALTH CARE; MOLECULES;

CLINICAL TESTS; INFECTION; MORBIDITY;

VIRUSES;

ANTIVIRUS AGENT; CILUPREVIR; ENZYME INHIBITOR; FURAPROFEN; HCV 086; HCV 371; HCV 796; HEPTAZYME; ISIS 14803; JTK 003; JTK 109; PROTEINASE INHIBITOR; RNA DEPENDENT RNA POLYMERASE INHIBITOR; SERINE PROTEINASE INHIBITOR; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; VALOPICITABINE; VX 950;

HEPATITIS;

ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MORBIDITY; PREVALENCE; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; MEMBRANE GLYCOPROTEINS; RECEPTORS, CELL SURFACE; RNA INTERFERENCE; TOLL-LIKE RECEPTORS;

HEPATITIS C VIRUS;

EID: 23944482649     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature04080     Document Type: Review

References (78)

1. Wasley, A. & Alter, M. J. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin. Liver Dis. 20, 1-16 (2000).
2. Brown, R. S. Jr & Gaglio, P. J. Scope of worldwide hepatitis C problem. Liver Transpl. 9, S10-S13 (2003).
3. Tomei, L., Altamura, S., Paonessa, G., De Francesco, R. & Migliaccio, G. HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase. Antiviral Chem. Chemother. 16, 225-245 (2005).
4. Urbani, A. et al. Substrate specificity of the hepatitis C virus serine protease NS3. J. Biol. Chem. 272, 9204-9209. (1997).
5. Yan, Y. et al. Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci. 7, 837-847 (1998).
6. Kim, J. L. et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87, 343-355 (1996).
7. Love, R. A. et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87, 331-342 (1996).
8. Llinas-Brunet, M. et al. Peptide-based inhibitors of the hepatitis C virus serine protease. Bioorg. Med. Chem. Lett. 8, 1713-1718 (1998).
9. Steinkuhler, C. et al. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry 37, 8899-8905 (1998).
10. Lamarre, D. et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426, 186-189 (2003).
11. Llinas-Brunet, M. et al. Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors. Bioorg. Med. Chem. Lett. 10, 2267-2270 (2000).
12. Goudreau, N. et al. NMR structural characterization of peptide inhibitors bound to the Hepatitis C virus NS3 protease: design of a new P2 substituent. J. Med. Chem. 47, 123-132 (2004).
13. Tsantrizos, Y. S. et al. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. Angew. Chem. Int. Ed. Engl. 42, 1356-1360 (2003).
14. Hinrichsen, H. et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127, 1347-1355 (2004).
15. Reiser, M. et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 41, 832-835 (2005).
16. Lu, L. et al. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob. Agents Chemother. 48, 2260-2266 (2004).
17. Lin, C. et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J. Biol. Chem. 279, 17508-17514 (2004).
18. Trozzi, C. et al. In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J. Virol. 77, 3669-3679 (2003).
19. Thibeault, D. et al. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061. J. Virol. 78, 7352-7359 (2004).
20. Chen, S.-H. et al. P1 and P1′ optimization of [3,4]-bicycloproline P2 incorporated tetrapeptidyl α-ketoamide based HCV protease inhibitors. Lett. Drug Des. Disc. 2, 118-123 (2005).
21. Vertex Pharmaceuticals reports that oral hepatitis C protease inhibitor VX-950 dramatically reduces viral levels in phase Ib clinical study. http://www.vrtx.com/Pressreleases2005/pr051705.html (2005).
22. Lemon, S. M., Yi, M. & Li, K. Strong reasons make strong actions. The antiviral efficacy of NS3/4A protease inhibitors. Hepatology 41, 671-673 (2005).
23. Lin, C. et al. In vitro resistance mutations against VX-950 and BILN 2061, two protease inhibitor clinical candidates: single-resistance, cross-resistance and fitness. Hepatology 40 (Suppl. 1), 404A (2004).
24. Behrens, S. E., Tomei, L. & De Francesco, R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J. 15, 12-22 (1996).
25. Ago, H. et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Struct. Fold. Des. 7, 1417-1426. (1999).
26. Bressanelli, S. et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl Acad. Sci. USA 96, 13034-13049. (1999).
27. Lesburg, C. A. et al. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nature Struct Biol. 6, 937-943. (1999).
28. Biswal, B. K. et al. Crystal structures of the RNA dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by nonnucleoside inhibitors. J. Biol. Chem. 280, 18202-18210 (2005).
29. Beaulieu, P. L. & Tsantrizos, Y. S. Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infections. Curr. Opin. Investig. Drugs 5, 838-850 (2004).
30. Afdhal, N. et al. Final phase I/II trial results for NM283, a new polymerase inhibitor for hepatitis C: antiviral efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures. http://www.idenix.com/products/datapres_nm283/AfdhalAASLD04_10-04.pdf(2004).
31. Standring, D. N. NM283 has potent antiviral activity against chronic hepatitis C virus, genotype 1, in the chimpanzee. http://www.idenix.com/ products/datapres_nm283/ StandringEASL2004_7-03.pdf (2004).
32. Carroll, S. et al. Susceptibility of different genotypes of hepatitis C virus to inhibition by nucleoside and nonnucleoside inhibitors. Antiviral Res. 62, A83 (2004).
33. Migliaccio, G. et al. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem. 278, 49164-49170 (2003).
34. Olsen, D. B. et al. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob Agents Chemother. 48, 3944-3953 (2004).
35. Afdal, N. et al. Enhanced antiviral efficacy for Valopicitabine (NM283) plus peg-interferon in hepatitis C patients with HCV genotype-1 infection: Results of a phase IIa multicenter trial. http://www.idenix.com/products/ datapres_nm283/AfdhalEASL2005_4-05.pdf (2005).
36. Ludmerer, S. W. et al. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob. Agents Chemother. 49, 2059-2069 (2005).
37. Hashimoto, H., Mizutani, K. & Yoshida, A. in WO 00147883 (Japan Tobacco Inc., Published International Patent Application, 2001).
38. LaPlante, S. R. et al. Binding mode determination of benzimidazole inhibitors of the hepatitis C virus RNA polymerase by a structure and dynamics strategy. Angew Chem. Int. Ed. Engl. 43, 4306-4311 (2004).
39. Tomei, L. et al. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 77, 13225-13231 (2003).
40. Di Marco, S. et al. Interdomain communication in hepatitis C virus polymerase abolished by small-molecule inhibitors bound to a novel allosteric site. J. Biol. Chem. published online 13 June 2005.
41. Lu, H. in WO 2005/000308 (Rigel Pharmaceuticals, USA. Published International Patent Application, 2005).
42. Poor bioavailability results in insignificant clinical effects for Rigel R803 in phase I/II HCV trial. http://www.rigel.com/rigel/pr_1101094254 (2004).
43. ViroPharma announces data from HCV-086 proof of concept study. http://phx.corporate-ir.net/phoenix.zhtml?c=92320&p=irol- researchNewsArticle&ID=684145&highlight (2005).
44. Chan, L. et al. Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 2: tertiary amides. Bioorg. Med. Chem. Lett. 14, 797-800 (2004).
45. Chan, L. et al. Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 1: Sulfonamides. Bioorg. Med. Chem. Lett. 14, 793-796 (2004).
46. Wang, M. et al. Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J. Biol. Chem. 278, 9489-9495 (2003).
47. Love, R. A. et al. Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme. J. Virol. 77, 7575-7581 (2003).
48. Dhanak, D. et al. Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J. Biol. Chem. 277, 38322-38327. (2002).
49. Gu, B. et al. Arresting initiation of hepatitis C virus RNA synthesis using heterocyclic derivatives. J. Biol. Chem. 278, 16602-16607 (2003).
50. Tomei, L. et al. Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J. Virol. 78, 938-946 (2004).
51. Nguyen, T. T. et al. Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase benzothiadiazine inhibitor. Antimicrob. Agents Chemother. 47, 3525-3530 (2003).
52. Braasch, D. A. et al. Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg. Med. Chem. Lett. 14, 1139-1143 (2004).
53. Foster, G. R. Past, present, and future hepatitis C treatments. Semin. Liver Dis. 24 (Suppl. 2), 97-104 (2004).
54. Kronke, J. et al. Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs. J. Virol. 78, 3436-3446 (2004).
55. Kapadia, S. B., Brideau-Andersen, A. & Chisari, F. V. Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc. Natl Acad Sci USA 100, 2014-2018 (2003).
56. Yokota, T. et al. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep. 4, 602-608 (2003).
57. Wilson, J. A. et al. RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proc Natl Acad. Sci. USA 100, 2783-2788 (2003).
58. Randall, G., Grakoui, A. & Rice, C. M. Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc. Natl Acad. Sci. USA 100, 235-240 (2003).
59. Song, E. et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nature Med. 9, 347-351 (2003).
60. Zender, L. et al. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc. Natl Acad. Sci. USA 100, 7797-7802 (2003).
61. McCaffrey, A. P. et al. RNA interference in adult mice. Nature 418, 38-39 (2002).
62. Han, J. et al. Inhibition of HCV replication in vivo by nuclease-resistant siRNAs that are targeted to the liver. Presented at 11th International Symp. Hepatitis C Virus and Related Viruses (Heidelberg, Germany 2004).
63. Wilson, J. A. & Richardson, C. D. Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region. J. Virol. 79, 7050-8 (2005).
64. Benitec announces clinical candidate for treatment of hepatitis C. http://www.benitec.com/PRDownloads/Hepatitis%20C%20Clinical%20Candidate%20 050905%20.pdf (2005).
65. O'Neill, L. A. TLRs: Professor Mechnikov, sit on your hat. Trends Immunol. 25, 687-693 (2004).
66. Takeda, K., Kaisho, T. & Akira, S. Toll-like receptors. Annu. Rev. Immunol. 21, 335-376 (2003).
67. Boehme, K. W. & Compton, T. Innate sensing of viruses by toll-like receptors. J. Virol. 78, 7867-7873 (2004).
68. Iwasaki, A. & Medzhitov, R. Toll-like receptor control of the adaptive immune responses. Nature Immunol. 5, 987-995 (2004).
69. Hahn, Y. S. Subversion of immune responses by hepatitis C virus: immunomodulatory strategies beyond evasion? Curr. Opin. Immunol. 15, 443-449 (2003).
70. McKenna, K., Beignon, A. S. & Bhardwaj, N. Plasmacytoid dendritic cells: linking innate and adaptive immunity. J. Virol. 79, 17-27 (2005).
71. Schetter, C. & Vollmer, J. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9. Curr. Opin. Drug Discov. Dev. 7, 204-210 (2004).
72. Coley reports results from phase I studies of Actilon™ for hepatitis C. http://www.coleypharma.com/coley/pr_1105025921 (2005).
73. Lee, J. et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc. Natl Acad. Sci. USA 100, 6646-6651 (2003).
74. Horsmans, Y. et al. Isatoribine, a Toll-like receptor 7 agonist, significantly reduced plasma viral load in a clinical proof-of-concept study in patients with chronic hepatitis C virus. Hepatology 40 (Suppl. 1), 282A (2004).
75. Anadys Pharmaceuticals announces selection of ANA975 as a development candidate for front-line treatment of chronic hepatitis C. http://phx.corporate- ir.net/phoenix.zhtml?c=148908&p=irol-newsArticle&ID=575761& highlight (2004).
76. Hannon, G. J. RNA interference. Nature 418, 244-251 (2002).
77. Elbashir, S. M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498 (2001).
78. Manoharan, M. RNA interference and chemically modified small interfering RNAs. Curr. Opin. Chem. Biol. 8, 570-579 (2004).